McInnes IB, Rahman P, Gottlieb AB, et al. - The phase III DISCOVER‐2 trial established the efficacy and safety of guselkumab vs placebo through week 24 in biologic‐naive patients with psoriatic arthritis (PsA). Researchers herein documented 1‐year DISCOVER‐2 findings. Despite standard nonbiologic treatment, 739 patients with active PsA (≥ 5 swollen and ≥ 5 tender joints; C‐reactive protein level ≥ 0.6 mg/dl) were allocated to receive subcutaneous injections of guselkumab 100 mg every 4 weeks, guselkumab 100 mg at week 0, week 4 and every 8 weeks thereafter, or placebo with crossover to guselkumab 100 mg every 4 weeks at week 24. Ninety-three percent of the randomized, treated patients, completed week 52. Outcomes revealed achievement of sustained improvements across diverse manifestations in biologic‐naive PsA patients in correlation with receiving guselkumab and the favorable risk–benefit profile of guselkumab remained maintained through week 52.